Screening of TGFBR1, TGFBR2, and FLNA in familial mitral valve prolapse

Jan J. J. Aalberts*, J. Peter van Tintelen, Toon Oomen, Jorieke E. H. Bergman, Dicky J. J. Halley, Jan D. H. Jongbloed, Albert J. H. Suurmeijer, Maarten P. van den Berg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


So far only mutations in the filamin A gene (FLNA) have been identified as causing familial mitral valve prolapse (MVP). Previous studies have linked dysregulation of the transforming growth factor beta (TGF-β) cytokine family to MVP. We investigated whether mutations in the TGF-β receptors genes type I (TGFBR1) and II (TGFBR2) underlie isolated familial MVP cases. Eight families with isolated familial MVP were evaluated clinically and genetically. Ventricular arrhythmias were present in five of the eight families and sudden cardiac death occurred in six patients. Tissue obtained during mitral valve surgery or autopsy was available for histological examination in six cases; all demonstrated myxomatous degeneration. A previously described FLNA missense mutation (p.G288R) was identified in one large family, but no mutations were discovered in TGFBR1 or TGFBR2. An FLNA missense mutation was identified in one family but we found no TGFBR1 or TGFBR2 mutations. Our results suggest that TGFBR1 and TGFBR2 mutations do not play a major role in isolated myxomatous valve dystrophy. Screening for FLNA mutations is recommended in familial myxomatous valvular dystrophy, particularly if X-linked inheritance is suspected.

Original languageEnglish
Pages (from-to)113-119
Number of pages7
JournalAmerican Journal of Medical Genetics. Part B: Neuropsychiatric Genetics
Issue number1
Publication statusPublished - Jan-2014


  • familial mitral valve prolapse
  • myxomatous degeneration
  • transforming growth factor beta
  • filamin

Cite this